During androgen-deprivation therapy, certain bacteria in the gut can synthesize androgens, thereby promoting tumor progression and therapy resistance.
Androgen-deprivation therapy (ADT) removes the hormones that fuel prostate tumor growth and is the standard treatment for advanced prostate cancer.
But cancers that initially respond to ADT (known as ‘hormone-sensitive prostate cancer’ (HSPC)) often develop resistance, evolving into castration-resistant prostate cancer (CRPC). Once this occurs, treatment options are limited.
More information, here.
